27.62 USD
-1.67 (-5.7%)
At close: Jan 30, 2026
28 USD
+0.38 (+1.38%)
After Hours: 1/30/2026, 5:37:29 PM
We assign a fundamental rating of 3 out of 10 to BEAM. BEAM was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. BEAM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year BEAM has reported negative net income.
- In the past year BEAM has reported a negative cash flow from operations.
- BEAM had negative earnings in each of the past 5 years.
- BEAM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- BEAM's Return On Assets of -31.63% is fine compared to the rest of the industry. BEAM outperforms 65.90% of its industry peers.
- BEAM's Return On Equity of -42.92% is fine compared to the rest of the industry. BEAM outperforms 69.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.63% | ||
| ROE | -42.92% | ||
| ROIC | N/A |
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for BEAM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BEAM has more shares outstanding
- BEAM has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- BEAM has an Altman-Z score of 2.86. This is not the best score and indicates that BEAM is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.86, BEAM is doing good in the industry, outperforming 68.57% of the companies in the same industry.
- BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.86 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- BEAM has a Current Ratio of 6.02. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
- BEAM's Current ratio of 6.02 is fine compared to the rest of the industry. BEAM outperforms 62.48% of its industry peers.
- A Quick Ratio of 6.02 indicates that BEAM has no problem at all paying its short term obligations.
- BEAM has a better Quick ratio (6.02) than 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.02 | ||
| Quick Ratio | 6.02 |
3. Growth
3.1 Past
- BEAM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -151.70%.
- Looking at the last year, BEAM shows a very negative growth in Revenue. The Revenue has decreased by -84.07% in the last year.
- BEAM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 401.62% yearly.
EPS 1Y (TTM)-151.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.98%
Revenue 1Y (TTM)-84.07%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-32.03%
3.2 Future
- Based on estimates for the next years, BEAM will show a small growth in Earnings Per Share. The EPS will grow by 7.78% on average per year.
- The Revenue is expected to grow by 52.84% on average over the next years. This is a very strong growth
EPS Next Y3.38%
EPS Next 2Y-1.86%
EPS Next 3Y-1.41%
EPS Next 5Y7.78%
Revenue Next Year-27.77%
Revenue Next 2Y-5.53%
Revenue Next 3Y4.19%
Revenue Next 5Y52.85%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
- Also next year BEAM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.86%
EPS Next 3Y-1.41%
5. Dividend
5.1 Amount
- No dividends for BEAM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BEAM THERAPEUTICS INC / BEAM FAQ
What is the ChartMill fundamental rating of BEAM THERAPEUTICS INC (BEAM) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BEAM.
Can you provide the valuation status for BEAM THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to BEAM THERAPEUTICS INC (BEAM). This can be considered as Overvalued.
Can you provide the profitability details for BEAM THERAPEUTICS INC?
BEAM THERAPEUTICS INC (BEAM) has a profitability rating of 1 / 10.
How financially healthy is BEAM THERAPEUTICS INC?
The financial health rating of BEAM THERAPEUTICS INC (BEAM) is 7 / 10.
What is the earnings growth outlook for BEAM THERAPEUTICS INC?
The Earnings per Share (EPS) of BEAM THERAPEUTICS INC (BEAM) is expected to grow by 3.38% in the next year.